SYROS PHARMACEUTICALS INC's ticker is SYRS and the CUSIP is 87184Q107. A total of 69 filers reported holding SYROS PHARMACEUTICALS INC in Q4 2018. The put-call ratio across all filers is - and the average weighting 0.1%.
Quarter-by-quarter ownership
| Value | Shares | Weighting | ||||
|---|---|---|---|---|---|---|
| Q1 2022 | $443,000 | -43.9% | 372,208 | +53.7% | 0.06% | -40.4% |
| Q4 2021 | $789,000 | +60.0% | 242,132 | +119.4% | 0.10% | +98.0% |
| Q3 2021 | $493,000 | -35.8% | 110,337 | -21.7% | 0.05% | -41.9% |
| Q2 2021 | $768,000 | +58.4% | 140,991 | +117.5% | 0.09% | +7.5% |
| Q1 2021 | $485,000 | +152.6% | 64,830 | +133.6% | 0.08% | +263.6% |
| Q4 2019 | $192,000 | +3.2% | 27,756 | +38.3% | 0.02% | +4.8% |
| Q2 2019 | $186,000 | -47.2% | 20,070 | -48.0% | 0.02% | -41.7% |
| Q1 2019 | $352,000 | +20.1% | 38,563 | -26.7% | 0.04% | +5.9% |
| Q4 2018 | $293,000 | -69.8% | 52,577 | -35.4% | 0.03% | -37.0% |
| Q3 2018 | $969,000 | +142.2% | 81,377 | +107.7% | 0.05% | +170.0% |
| Q2 2018 | $400,000 | -71.7% | 39,177 | -64.0% | 0.02% | -73.3% |
| Q1 2018 | $1,414,000 | +489.2% | 108,900 | +568.1% | 0.08% | +368.8% |
| Q3 2017 | $240,000 | – | 16,300 | – | 0.02% | – |
Download | ||||||
Other shareholders
| Name | Shares | Value | Weighting ↓ |
|---|---|---|---|
| Flagship Pioneering Inc. | 4,806,656 | $58,449,000 | 19.02% |
| Casdin Capital, LLC | 182,141 | $2,215,000 | 1.83% |
| Aisling Capital LLC | 508,565 | $6,184,000 | 1.44% |
| Redmile Group, LLC | 948,440 | $11,533,000 | 0.99% |
| DEERFIELD MANAGEMENT COMPANY, L.P. (SERIES C) | 1,812,778 | $22,043,000 | 0.91% |
| EcoR1 Capital, LLC | 63,596 | $773,000 | 0.25% |
| Eventide Asset Management | 150,000 | $1,824,000 | 0.12% |
| AWM Investment Company, Inc. | 47,550 | $578,000 | 0.11% |
| Weiss Multi-Strategy Advisers LLC | 49,000 | $596,000 | 0.03% |
| Baker Brothers Advisors | 204,465 | $2,486,000 | 0.02% |